Evidence map›Paper›PMID 36038831›Full record

ArticleBMC cancer2022

Identification and functional analysis of LncRNA-XIST ceRNA network in prostate cancer.

Jie Wang, Jie Huang, Yingxue Guo, Yuli Fu, Yifang Cao, Kang Zhou, Jianxiong Ma, Bodong Lv, Wenjie Huang

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Jie Wang *The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Jie Huang *The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Yingxue GuoCollege of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, China.
Yuli FuThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Yifang CaoUrology Department, Jiaxing First Hospital, Affiliated Hospital of Jiaxing University, Jiaxing, Zhejiang, China.
Kang ZhouThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Jianxiong MaThe Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
Bodong LvDepartment of Urology, School of Medicine, The Second Affiliated Hospital, Zhejia-Ng University, Hangzhou, China. lbd168@zju.edu.cn.
Wenjie HuangDepartment of Urology, School of Medicine, The Second Affiliated Hospital, Zhejia-Ng University, Hangzhou, China. huangwenjie@zju.edu.cn.
Zhejiang Chinese Medical University · CNSecond Affiliated Hospital of Zhejiang University · CNJiaxing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLong non-coding RNAs (lncRNAs) play a functional role in the progression of prostate cancer (PCa). However, the molecular mechanism, expression, or function of the lncRNA XIST in PCa is not well understood. Therefore, the major goal of this study was to investigate the involvement of XIST in PCa.

methodsWe used the The Cancer Genome Atlas (TCGA) database to conduct a pan-cancer bioinformatics analysis of XIST and identified that it may play an important role in prostate cancer. This finding was verified using clinical samples and in vitro assays. Finally, we constructed an XIST ceRNA network for prostate cancer.

resultsOur in vitro and in vivo results showed that the XIST gene expression level was higher in PCa derived cells and tissues compared to that in normal cells and tissues. XIST gene expression level was positively correlated with the invasion and proliferation of tumour cells. Furthermore, the downregulation of XIST inhibited the growth of subcutaneous 22Rv1 xenografts in nude mice. In addition, we constructed a XIST ceRNA network. Consistent with previous studies, we found that the role of XIST is mediated through via sponges, such as miRNA -96-5p, miRNA -153-3p, and miRNA-182-5p.

conclusionHigh expression level of XIST can lead to enhanced carcinogenicity in PCa. Therefore, XIST has the potential to be used as a prognostic marker and may become a new research focus for the treatment of PCa.

Indexed as

MicroRNAsProstatic NeoplasmsRNA, Long NoncodingAnimalsDown-RegulationHumansMaleMiceMice, NudeMicroRNAsMirn182 microRNA, humanRNA, Long NoncodingceRNA networkLncRNA-XISTMigrationProliferationProstate cancer

Identifiers

PMID36038831
PMCPMC9426231
OpenAlexW4293499849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.